NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Price Target & More

$88.29 +0.26 (+0.30 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$88.29
Today's Range$87.15 - $88.81
52-Week Range$45.11 - $89.33
Volume328,776 shs
Average Volume581,306 shs
Market Capitalization$4.98 billion
P/E Ratio-13.08
Dividend YieldN/A
Beta1.98

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Debt-to-Equity RatioN/A
Current Ratio4.69%
Quick Ratio4.69%

Price-To-Earnings

Trailing P/E Ratio-13.08
Forward P/E Ratio-14.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$43.01 million
Price / Sales117.69
Cash FlowN/A
Price / CashN/A
Book Value$7.69 per share
Price / Book11.48

Profitability

EPS (Most Recent Fiscal Year)($6.75)
Net Income$-314,670,000.00
Net Margins-731.60%
Return on Equity-76.67%
Return on Assets-48.05%

Miscellaneous

Employees382
Outstanding Shares57,330,000

How to Become a New Pot Stock Millionaire

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals (NASDAQ:AGIO) posted its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.65) by $0.16. The biopharmaceutical company had revenue of $9.80 million for the quarter, compared to analyst estimates of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. Agios Pharmaceuticals's quarterly revenue was down 56.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.34) earnings per share. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, May, 4th 2018. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

11 analysts have issued 12 month price objectives for Agios Pharmaceuticals' shares. Their forecasts range from $75.00 to $101.00. On average, they expect Agios Pharmaceuticals' share price to reach $87.3333 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:
  • 1. Cann analysts commented, "While we have not modeled any revenue impact from AG-270 to either Agios or Celgene by 2022, we believe that AG-270 could be an important value driver for Agios and Celgene. AG-270 is a novel compound in the field of synthetic lethality, and has the potential to address large patient populations. We are not making any changes to our outlook at this time, but we continue to watch the timing of the program closely." (4/17/2018)
  • 2. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for  AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:
  • Dr. David P. Schenkein M.D., CEO, Pres & Director (Age 61)
  • Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 69)
  • Mr. Andrew Hirsch, Chief Financial Officer (Age 47)
  • Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 62)
  • Dr. Christopher Bowden, Chief Medical Officer (Age 57)

Has Agios Pharmaceuticals been receiving favorable news coverage?

Press coverage about AGIO stock has been trending somewhat positive on Thursday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a news impact score of 0.13 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.32 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include CELGENE EUROPEAN INVESTMENT COMPANY LLC (12.10%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $88.29.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $4.98 billion and generates $43.01 million in revenue each year. The biopharmaceutical company earns $-314,670,000.00 in net income (profit) each year or ($6.75) on an earnings per share basis. Agios Pharmaceuticals employs 382 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (AGIO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  520
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agios Pharmaceuticals (NASDAQ:AGIO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Agios Pharmaceuticals in the last 12 months. Their average twelve-month price target is $87.3333, suggesting that the stock has a possible downside of 1.08%. The high price target for AGIO is $101.00 and the low price target for AGIO is $75.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.732.912.92
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $87.3333$85.6667$77.00$75.20
Price Target Upside: 1.08% downside9.87% upside9.48% upside8.53% upside

Agios Pharmaceuticals (NASDAQ:AGIO) Consensus Price Target History

Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018CannReiterated RatingHoldLowView Rating Details
4/11/2018Credit Suisse GroupSet Price TargetOutperform -> Buy$80.00 -> $95.00MediumView Rating Details
2/15/2018SunTrust BanksReiterated RatingBuy -> Buy$80.00 -> $101.00LowView Rating Details
2/15/2018JPMorgan ChaseBoost Price TargetOverweight -> Overweight$76.00 -> $85.00LowView Rating Details
2/15/2018Needham & Company LLCBoost Price TargetBuy -> Buy$72.00 -> $86.00LowView Rating Details
2/14/2018OppenheimerDowngradeOutperform -> Market PerformLowView Rating Details
2/14/2018UBSDowngradeOutperform -> Market PerformLowView Rating Details
1/18/2018Royal Bank of CanadaBoost Price TargetOutperform$91.00MediumView Rating Details
12/12/2017Canaccord GenuitySet Price TargetBuy$90.00HighView Rating Details
8/2/2017Leerink SwannUpgradeMarket Perform -> Outperform$50.00 -> $80.00HighView Rating Details
8/1/2017Janney Montgomery ScottReiterated RatingHoldHighView Rating Details
2/16/2017CowenReiterated RatingBuyN/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman SachsReiterated RatingNeutral$46.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings History and Estimates Chart

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings Estimates

2018 EPS Consensus Estimate: ($5.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.65)($1.57)($1.61)
Q2 20183($1.63)($1.44)($1.55)
Q3 20183($1.89)($1.42)($1.66)
Q4 20183($1.53)($0.58)($1.15)

Agios Pharmaceuticals (NASDAQ AGIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($1.68)N/AView Earnings Details
2/14/2018Q4 2017($1.65)($1.81)$12.65 million$9.80 millionViewListenView Earnings Details
11/1/2017Q3 2017($1.78)($1.59)$10.85 million$11.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.57)($1.78)$10.68 million$11.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)$6.22 million$6.27 millionViewListenView Earnings Details
9/5/2013Q2 2013($0.28)($2.80)$6.19 million$6.27 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Agios Pharmaceuticals (NASDAQ:AGIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.43%
Institutional Ownership Percentage: 82.41%
Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/12/2018Christopher BowdenInsiderSell2,000$85.10$170,200.002,881View SEC Filing  
4/5/2018Scott BillerInsiderSell3,000$75.20$225,600.0060,196View SEC Filing  
4/2/2018David P SchenkeinCEOSell13,000$77.72$1,010,360.00View SEC Filing  
3/22/2018Steven L HoerterInsiderSell2,050$84.65$173,532.502,050View SEC Filing  
3/19/2018Kaye I Foster-CheekDirectorSell6,800$81.97$557,396.009,000View SEC Filing  
3/16/2018David ScaddenDirectorBuy200$83.44$16,688.00571View SEC Filing  
3/5/2018Scott BillerInsiderSell3,000$83.08$249,240.00View SEC Filing  
3/1/2018David P SchenkeinCEOSell13,000$81.09$1,054,170.00View SEC Filing  
2/22/2018Steven L HoerterInsiderSell2,050$78.63$161,191.502,050View SEC Filing  
2/16/2018Christopher BowdenInsiderSell2,000$77.65$155,300.00View SEC Filing  
2/5/2018Scott BillerInsiderSell3,000$76.04$228,120.00View SEC Filing  
2/1/2018Christopher BowdenInsiderSell2,000$78.75$157,500.002,881View SEC Filing  
2/1/2018David P SchenkeinCEOSell13,000$78.75$1,023,750.0013,000View SEC Filing  
1/26/2018David P SchenkeinCEOSell23,572$81.09$1,911,453.4823,572View SEC Filing  
1/24/2018David P SchenkeinCEOSell46,408$80.01$3,713,104.0832,875View SEC Filing  
1/23/2018Corp /De/ CelgeneMajor ShareholderBuy851,154$67.00$57,027,318.001,374,599View SEC Filing  
1/23/2018Steven L HoerterInsiderSell25,000$74.83$1,870,750.0025,000View SEC Filing  
1/16/2018David P SchenkeinCEOSell53,000$73.16$3,877,480.0053,000View SEC Filing  
1/12/2018Carman AlensonInsiderSell2,150$75.00$161,250.002,150View SEC Filing  
1/10/2018Scott BillerInsiderSell3,000$65.00$195,000.0056,059View SEC Filing  
12/7/2017Lewis Clayton Jr. CantleyDirectorSell3,838$59.37$227,862.0680,851View SEC Filing  
12/1/2017David P SchenkeinCEOSell6,000$61.55$369,300.006,000View SEC Filing  
12/1/2017Scott BillerInsiderSell2,146$60.79$130,455.348,410View SEC Filing  
11/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$60.88$243,520.0082,394View SEC Filing  
11/1/2017David P SchenkeinCEOSell6,000$63.85$383,100.00View SEC Filing  
11/1/2017Scott BillerInsiderSell2,146$62.69$134,532.74View SEC Filing  
10/17/2017Lewis Clayton Jr. CantleyDirectorSell4,000$71.10$284,400.0084,394View SEC Filing  
10/16/2017Lewis Clayton Jr. CantleyDirectorSell1,000$71.09$71,090.0084,394View SEC Filing  
10/4/2017David P SchenkeinCEOSell80,000$70.14$5,611,200.00View SEC Filing  
10/4/2017Scott BillerInsiderSell10,470$70.00$732,900.00View SEC Filing  
10/2/2017David P SchenkeinCEOSell6,000$66.76$400,560.00View SEC Filing  
10/2/2017Scott BillerInsiderSell2,146$67.23$144,275.58View SEC Filing  
9/18/2017David P SchenkeinCEOSell35,000$67.12$2,349,200.0035,000View SEC Filing  
9/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$65.59$262,360.0086,394View SEC Filing  
9/13/2017Lewis Clayton Jr. CantleyDirectorSell1,000$65.47$65,470.0086,394View SEC Filing  
9/11/2017Scott BillerInsiderSell15,000$65.00$975,000.006,264View SEC Filing  
9/1/2017David P SchenkeinCEOSell6,000$62.20$373,200.006,000View SEC Filing  
9/1/2017Scott BillerInsiderSell2,146$61.99$133,030.548,410View SEC Filing  
8/23/2017Lewis Clayton Jr. CantleyDirectorSell4,000$56.85$227,400.00View SEC Filing  
8/2/2017David P SchenkeinCEOSell27,000$59.95$1,618,650.003,000View SEC Filing  
8/2/2017Scott BillerInsiderSell23,146$59.60$1,379,501.608,410View SEC Filing  
7/20/2017Lewis Clayton Jr. CantleyDirectorSell9,000$56.36$507,240.0086,697View SEC Filing  
7/19/2017Lewis Clayton Jr. CantleyDirectorSell3,500$56.14$196,490.0086,697View SEC Filing  
7/7/2017Scott BillerInsiderSell2,146$55.00$118,030.008,410View SEC Filing  
7/3/2017David P SchenkeinCEOSell3,000$51.18$153,540.003,000View SEC Filing  
6/21/2017Scott BillerInsiderSell4,292$55.00$236,060.00View SEC Filing  
6/14/2017Lewis Clayton Jr. CantleyDirectorSell2,000$50.87$101,740.0090,197View SEC Filing  
6/7/2017David P SchenkeinCEOSell3,000$50.02$150,060.001,100View SEC Filing  
5/25/2017Lewis Clayton Jr. CantleyDirectorSell2,036$47.10$95,895.6091,206View SEC Filing  
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.003,000View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.3093,751View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.6493,751View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.003,000View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.9694,769View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.0021,403View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16109,230View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52109,230View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.6873,078View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.006,000View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76108,405View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.0048,270View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00109,659View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05109,659View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.0048,270View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87110,913View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87110,913View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20112,167View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95112,167View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52125,921View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99125,921View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.0081,376View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76127,175View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76128,429View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00128,429View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76129,683View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60131,086View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72131,713View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52132,967View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.0061,835View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64138,299View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.0081,835View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.0034,070View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64143,002View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.0081,835View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.0034,070View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00147,854View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00141,835View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00131,835View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00200,090View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00205,090View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.0030,000View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.0046,583View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00209,090View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00209,090View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.0030,000View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86109,090View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00109,090View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agios Pharmaceuticals (NASDAQ AGIO) News Headlines

Source:
DateHeadline
Agios' Leukemia Drug Bodes Well for Growth & Strong PipelineAgios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
finance.yahoo.com - April 18 at 5:46 PM
Cann Reaffirms "Hold" Rating for Agios Pharmaceuticals (AGIO)Cann Reaffirms "Hold" Rating for Agios Pharmaceuticals (AGIO)
www.americanbankingnews.com - April 17 at 11:37 AM
Christopher Bowden Sells 2,000 Shares of Agios Pharmaceuticals (AGIO) StockChristopher Bowden Sells 2,000 Shares of Agios Pharmaceuticals (AGIO) Stock
www.americanbankingnews.com - April 16 at 4:27 PM
Agios Pharmaceuticals (AGIO) Hold Rating Reaffirmed at Janney Montgomery ScottAgios Pharmaceuticals' (AGIO) Hold Rating Reaffirmed at Janney Montgomery Scott
www.americanbankingnews.com - April 14 at 10:05 AM
Agios Pharmaceuticals (AGIO) Upgraded by Leerink Swann to "Outperform"Agios Pharmaceuticals (AGIO) Upgraded by Leerink Swann to "Outperform"
www.americanbankingnews.com - April 14 at 10:05 AM
$13.59 Million in Sales Expected for Agios Pharmaceuticals (AGIO) This Quarter$13.59 Million in Sales Expected for Agios Pharmaceuticals (AGIO) This Quarter
www.americanbankingnews.com - April 14 at 4:21 AM
Agios Pharmaceuticals (AGIO) Expected to Announce Earnings of -$1.60 Per ShareAgios Pharmaceuticals (AGIO) Expected to Announce Earnings of -$1.60 Per Share
www.americanbankingnews.com - April 12 at 9:07 AM
Agios Pharmaceuticals (AGIO) Stock Rating Lowered by BidaskClubAgios Pharmaceuticals (AGIO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 11 at 10:42 PM
Credit Suisse Group Reiterates "$95.00" Price Target for Agios Pharmaceuticals (AGIO)Credit Suisse Group Reiterates "$95.00" Price Target for Agios Pharmaceuticals (AGIO)
www.americanbankingnews.com - April 11 at 9:21 AM
Needham & Company LLC Raises Agios Pharmaceuticals (AGIO) Price Target to $72.00Needham & Company LLC Raises Agios Pharmaceuticals (AGIO) Price Target to $72.00
www.americanbankingnews.com - April 10 at 11:38 PM
Scott Biller Sells 3,000 Shares of Agios Pharmaceuticals (AGIO) StockScott Biller Sells 3,000 Shares of Agios Pharmaceuticals (AGIO) Stock
www.americanbankingnews.com - April 9 at 7:19 PM
Why Alcoa, Merck, and Agios Pharmaceuticals Jumped TodayWhy Alcoa, Merck, and Agios Pharmaceuticals Jumped Today
finance.yahoo.com - April 9 at 5:23 PM
ASLAN Pharmaceuticals Files For $86 Million US IPOASLAN Pharmaceuticals Files For $86 Million US IPO
seekingalpha.com - April 7 at 8:22 AM
David P. Schenkein Sells 13,000 Shares of Agios Pharmaceuticals (AGIO) StockDavid P. Schenkein Sells 13,000 Shares of Agios Pharmaceuticals (AGIO) Stock
www.americanbankingnews.com - April 4 at 10:40 PM
Agios Pharmaceuticals (AGIO) Rating Increased to Buy at ValuEngineAgios Pharmaceuticals (AGIO) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
Analysts’ Ratings for Athenex and Its Peers in MarchAnalysts’ Ratings for Athenex and Its Peers in March
finance.yahoo.com - April 2 at 8:37 AM
Agios Pharmaceuticals (AGIO) Given New $66.00 Price Target at Credit Suisse GroupAgios Pharmaceuticals (AGIO) Given New $66.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - April 1 at 10:52 PM
ValuEngine Upgrades Agios Pharmaceuticals (AGIO) to "Hold"ValuEngine Upgrades Agios Pharmaceuticals (AGIO) to "Hold"
www.americanbankingnews.com - March 31 at 3:48 PM
Oppenheimer Analysts Give Agios Pharmaceuticals (AGIO) a $83.00 Price TargetOppenheimer Analysts Give Agios Pharmaceuticals (AGIO) a $83.00 Price Target
www.americanbankingnews.com - March 31 at 2:06 PM
Agios Pharmaceuticals (AGIO) Receives Average Rating of "Buy" from AnalystsAgios Pharmaceuticals (AGIO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 31 at 11:34 AM
How Analysts View Agios Pharmaceuticals and Peers in March 2018How Analysts View Agios Pharmaceuticals and Peers in March 2018
finance.yahoo.com - March 30 at 8:20 AM
An Insight into Agios Pharmaceuticals’ Product PipelineAn Insight into Agios Pharmaceuticals’ Product Pipeline
finance.yahoo.com - March 30 at 8:20 AM
Exploring Agios Pharmaceuticals’ Cash FlowsExploring Agios Pharmaceuticals’ Cash Flows
finance.yahoo.com - March 30 at 8:20 AM
Agios Pharmaceuticals (AGIO) Upgraded to Buy by Zacks Investment ResearchAgios Pharmaceuticals (AGIO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:18 PM
Agios Pharmaceuticals (AGIO) Stock Rating Upgraded by Zacks Investment ResearchAgios Pharmaceuticals (AGIO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 28 at 12:58 PM
Agios Pharmaceuticals (AGIO) Raised to "Buy" at BidaskClubAgios Pharmaceuticals (AGIO) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - March 28 at 11:57 AM
 Brokerages Expect Agios Pharmaceuticals (AGIO) Will Announce Quarterly Sales of $13.59 Million Brokerages Expect Agios Pharmaceuticals (AGIO) Will Announce Quarterly Sales of $13.59 Million
www.americanbankingnews.com - March 28 at 8:09 AM
Insider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells 2,050 Shares of StockInsider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells 2,050 Shares of Stock
www.americanbankingnews.com - March 26 at 4:10 PM
Agios Pharmaceuticals (AGIO) Upgraded to Hold at ValuEngineAgios Pharmaceuticals (AGIO) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Juno Therapeutics And Agios: Two Really Big Fish That Got AwayJuno Therapeutics And Agios: Two Really Big Fish That Got Away
www.forbes.com - March 24 at 8:48 AM
Kaye I. Foster-Cheek Sells 6,800 Shares of Agios Pharmaceuticals Inc (AGIO) StockKaye I. Foster-Cheek Sells 6,800 Shares of Agios Pharmaceuticals Inc (AGIO) Stock
www.americanbankingnews.com - March 21 at 4:08 PM
Wired News – Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted TumorsWired News – Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted Tumors
finance.yahoo.com - March 21 at 8:45 AM
Agios Pharmaceuticals Inc (AGIO) Director David Scadden Purchases 200 SharesAgios Pharmaceuticals Inc (AGIO) Director David Scadden Purchases 200 Shares
www.americanbankingnews.com - March 20 at 8:32 PM
BRIEF-Agios Says First Patient Dosed In Lymphoma StudyBRIEF-Agios Says First Patient Dosed In Lymphoma Study
www.reuters.com - March 19 at 5:19 PM
Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid ... - GlobeNewswire (press release)Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid ... - GlobeNewswire (press release)
globenewswire.com - March 19 at 8:20 AM
Agios Pharma (AGIO) Reports 1st Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study - StreetInsider.comAgios Pharma (AGIO) Reports 1st Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study - StreetInsider.com
www.streetinsider.com - March 19 at 8:20 AM
Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP DeletionAgios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion
finance.yahoo.com - March 19 at 8:20 AM
Whats Happening with These Biotech Stocks? -- Aeterna Zentaris, Affimed, Agenus, and Agios Pharma - PR Newswire (press release)What's Happening with These Biotech Stocks? -- Aeterna Zentaris, Affimed, Agenus, and Agios Pharma - PR Newswire (press release)
www.prnewswire.com - March 13 at 8:23 AM
Zacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) Will Post Quarterly Sales of $13.42 MillionZacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) Will Post Quarterly Sales of $13.42 Million
www.americanbankingnews.com - March 11 at 9:46 AM
-$1.60 EPS Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter-$1.60 EPS Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter
www.americanbankingnews.com - March 9 at 1:27 AM
Agios Pharmaceuticals Inc (AGIO) Insider Sells $249,240.00 in StockAgios Pharmaceuticals Inc (AGIO) Insider Sells $249,240.00 in Stock
www.americanbankingnews.com - March 7 at 6:50 PM
Agios Pharmaceuticals Inc (AGIO) Receives Average Rating of "Buy" from AnalystsAgios Pharmaceuticals Inc (AGIO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 11:44 AM
Agios Pharmaceuticals Inc (AGIO) CEO David P. Schenkein Sells 13,000 SharesAgios Pharmaceuticals Inc (AGIO) CEO David P. Schenkein Sells 13,000 Shares
www.americanbankingnews.com - March 5 at 6:40 PM
Agios Pharmaceuticals Inc (AGIO) Stake Boosted by UBS Asset Management Americas Inc.Agios Pharmaceuticals Inc (AGIO) Stake Boosted by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 4 at 10:46 AM
Agios Pharmaceuticals Inc (AGIO) Stake Boosted by Swiss National BankAgios Pharmaceuticals Inc (AGIO) Stake Boosted by Swiss National Bank
www.americanbankingnews.com - March 4 at 8:22 AM
Agios Pharmaceuticals (AGIO) Upgraded at BidaskClubAgios Pharmaceuticals (AGIO) Upgraded at BidaskClub
www.americanbankingnews.com - March 3 at 6:10 PM
Eaton Vance Management Acquires 43,741 Shares of Agios Pharmaceuticals Inc (AGIO)Eaton Vance Management Acquires 43,741 Shares of Agios Pharmaceuticals Inc (AGIO)
www.americanbankingnews.com - March 2 at 12:05 PM
Agios Pharmaceuticals Inc (AGIO) Insider Steven L. Hoerter Sells 2,050 SharesAgios Pharmaceuticals Inc (AGIO) Insider Steven L. Hoerter Sells 2,050 Shares
www.americanbankingnews.com - February 26 at 6:50 PM
Brown Advisory Inc. Has $17.41 Million Holdings in Agios Pharmaceuticals Inc (AGIO)Brown Advisory Inc. Has $17.41 Million Holdings in Agios Pharmaceuticals Inc (AGIO)
www.americanbankingnews.com - February 25 at 4:36 AM
$13.42 Million in Sales Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter$13.42 Million in Sales Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter
www.americanbankingnews.com - February 22 at 6:08 AM

SEC Filings

Agios Pharmaceuticals (NASDAQ:AGIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agios Pharmaceuticals (NASDAQ:AGIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agios Pharmaceuticals (NASDAQ AGIO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.